MA27766A1 - Ligands de recepteurs de cannabinoides et leurs utilisations - Google Patents
Ligands de recepteurs de cannabinoides et leurs utilisationsInfo
- Publication number
- MA27766A1 MA27766A1 MA28565A MA28565A MA27766A1 MA 27766 A1 MA27766 A1 MA 27766A1 MA 28565 A MA28565 A MA 28565A MA 28565 A MA28565 A MA 28565A MA 27766 A1 MA27766 A1 MA 27766A1
- Authority
- MA
- Morocco
- Prior art keywords
- cannabinoid receptor
- receptor ligands
- ligands
- cannabinoid
- memo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
Ligands de récepteurs de cannabinoïdes et leurs utilisations Des composés de formules (I) et (II) qui jouent le rôle de ligands des récepteurs de cannabinoïdes et leurs utilisations dans le traitement de maladies liées à la médiation des récepteurs de cannabinoïdes chez des animaux sont décrits dans le présent mémoire.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46490803P | 2003-04-23 | 2003-04-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27766A1 true MA27766A1 (fr) | 2006-02-01 |
Family
ID=33310977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28565A MA27766A1 (fr) | 2003-04-23 | 2005-10-21 | Ligands de recepteurs de cannabinoides et leurs utilisations |
Country Status (31)
Country | Link |
---|---|
US (1) | US20040214856A1 (fr) |
EP (1) | EP1622903B1 (fr) |
JP (1) | JP2006524225A (fr) |
KR (1) | KR20060006048A (fr) |
CN (1) | CN1809566A (fr) |
AP (1) | AP2005003427A0 (fr) |
AR (1) | AR044037A1 (fr) |
AT (1) | ATE409700T1 (fr) |
AU (1) | AU2004232552A1 (fr) |
BR (1) | BRPI0409791A (fr) |
CA (1) | CA2521538A1 (fr) |
CL (1) | CL2004000827A1 (fr) |
CO (1) | CO5640084A2 (fr) |
DE (1) | DE602004016839D1 (fr) |
EA (1) | EA200501504A1 (fr) |
EC (1) | ECSP056117A (fr) |
ES (1) | ES2309517T3 (fr) |
GT (1) | GT200400076A (fr) |
IS (1) | IS8054A (fr) |
MA (1) | MA27766A1 (fr) |
MX (1) | MXPA05011454A (fr) |
NL (1) | NL1026027C2 (fr) |
NO (1) | NO20055516L (fr) |
OA (1) | OA13047A (fr) |
PA (1) | PA8600601A1 (fr) |
PE (1) | PE20050419A1 (fr) |
TN (1) | TNSN05272A1 (fr) |
TW (1) | TW200510419A (fr) |
UY (1) | UY28276A1 (fr) |
WO (1) | WO2004094421A1 (fr) |
ZA (1) | ZA200508568B (fr) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2294330T3 (es) * | 2002-08-02 | 2008-04-01 | MERCK & CO., INC. | Derivados de furo(2,3-b)piridina sustituidos. |
AU2003275242B2 (en) | 2002-09-27 | 2010-03-04 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
EP1603585A2 (fr) * | 2003-03-14 | 2005-12-14 | Bristol-Myers Squibb Company | Polynucleotide codant un nouveau variant de recepteur de hm74, hgprbmy74 couple a une proteine g humaine |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7141669B2 (en) * | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
MXPA05011922A (es) * | 2003-05-07 | 2006-02-17 | Pfizer Prod Inc | Ligandos del receptor de cannabinoides y sus usos. |
US7232823B2 (en) * | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US20050026983A1 (en) * | 2003-07-30 | 2005-02-03 | Pfizer Inc | Imidazole compounds and uses thereof |
JP2007510649A (ja) * | 2003-11-04 | 2007-04-26 | メルク エンド カムパニー インコーポレーテッド | 置換ナフチリジノン誘導体 |
US7151097B2 (en) * | 2003-11-07 | 2006-12-19 | Pfizer Inc. | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof |
DE602005010698D1 (de) | 2004-06-09 | 2008-12-11 | Glaxo Group Ltd | Pyrrolopyridinderivate |
US20060025448A1 (en) | 2004-07-22 | 2006-02-02 | Cadila Healthcare Limited | Hair growth stimulators |
CA2585925C (fr) * | 2004-10-27 | 2014-04-22 | Janssen Pharmaceutica, N.V. | Agents regulateurs de cannabinoides de type tetrahydropyridinylpyrazole |
BRPI0519124A2 (pt) * | 2004-12-17 | 2008-12-23 | Lilly Co Eli | composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço |
US20060223798A1 (en) | 2005-03-31 | 2006-10-05 | Fina Liotta | Tetrahydrothiopyrano pyrazole cannabinoid modulators |
EP1874779A1 (fr) * | 2005-04-20 | 2008-01-09 | Pfizer Products Inc. | Composes heteromatiques acylaminobicycliques tenant lieu de ligands du recepteur cannabinoide |
CA2609783A1 (fr) * | 2005-05-27 | 2006-12-07 | Pfizer Products Inc. | Polytherapie pour le traitement de l'obesite ou le maintien du poids apres une perte ponderale |
CA2618165A1 (fr) * | 2005-08-09 | 2007-02-15 | Glaxo Group Limited | Derives de l'imidazopyridine comme ligands du recepteur cannabinoide |
US7872006B2 (en) | 2005-10-21 | 2011-01-18 | Mitsubishi Tanabe Pharma Corporation | Pyrazole compounds having cannabinoid receptor (CB1) antagonizing activity |
WO2007102999A2 (fr) * | 2006-02-21 | 2007-09-13 | Ampla Pharmaceuticals Inc. | Antagonistes et agonistes inverses du cb1 |
AU2007283113A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
WO2008039863A2 (fr) * | 2006-09-27 | 2008-04-03 | Braincells, Inc. | Modulation de la neurogenèse médiée par le récepteur de la mélanocortine |
PE20090142A1 (es) * | 2007-04-11 | 2009-02-19 | Merck & Co Inc | Derivados de furo[2,3-b] piridina sustituidos como moduladores del receptor canabinoide-1 |
EP2025674A1 (fr) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament |
EP2242745A1 (fr) * | 2008-02-07 | 2010-10-27 | Sanofi-Aventis | Nouvelles imidazolidines substituées par un phényle, procédé de production, médicaments contenant ces composés et leur utilisation |
UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
JO2870B1 (en) * | 2008-11-13 | 2015-03-15 | ميرك شارب اند دوهم كورب | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes |
WO2010068601A1 (fr) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant |
CA2771278A1 (fr) | 2009-08-26 | 2011-03-03 | Sanofi | Nouveaux hydrates de fluoroglycoside heteroaromatiques cristallins, substances pharmaceutiques comprenant ces composes et leur utilisation |
WO2011037793A1 (fr) | 2009-09-25 | 2011-03-31 | Merck Sharp & Dohme Corp. | Aminopipéridines substituées utilisées en tant qu'inhibiteurs de la dipeptidyl peptidase-iv dans le cadre du traitement du diabète |
EP2582709B1 (fr) | 2010-06-18 | 2018-01-24 | Sanofi | Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683699B1 (fr) | 2011-03-08 | 2015-06-24 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
WO2012120052A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation |
WO2012120058A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés d'oxathiazine substitués par des groupes benzyle ou hétérométhylène, leur procédé de production, leur utilisation comme médicament ainsi que produits pharmaceutiques les contenant et leur utilisation |
US8809325B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof |
WO2012120053A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation |
US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120057A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation |
US9365576B2 (en) | 2012-05-24 | 2016-06-14 | Novartis Ag | Pyrrolopyrrolidinone compounds |
US9556180B2 (en) | 2013-01-22 | 2017-01-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction |
WO2014115077A1 (fr) | 2013-01-22 | 2014-07-31 | Novartis Ag | Composés de purinone substitués |
MX2015016344A (es) | 2013-05-27 | 2016-03-01 | Novartis Ag | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. |
PL3004112T3 (pl) | 2013-05-28 | 2018-02-28 | Novartis Ag | Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby |
MX2015016421A (es) | 2013-05-28 | 2016-03-03 | Novartis Ag | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. |
EP3071571A1 (fr) | 2013-11-21 | 2016-09-28 | Novartis AG | Dérivés de pyrrolopyrrolone et leur utilisation en tant qu'inhibiteurs de protéines bet |
SG10202006688RA (en) * | 2016-03-11 | 2020-08-28 | Ac Immune Sa | Bicyclic compounds for diagnosis and therapy |
CN105878251B (zh) * | 2016-04-22 | 2019-04-09 | 上海市同济医院 | 帕金森病动物模型的制备方法及其用途 |
KR102586710B1 (ko) | 2017-05-31 | 2023-10-10 | 케모센트릭스, 인크. | C5a 억제제로서의 5-5 융합 고리 |
EP3630775B1 (fr) | 2017-05-31 | 2022-12-14 | ChemoCentryx, Inc. | Cycles 6-5 fusionnés utilisés en tant qu'inhibiteurs de c5a |
WO2019126431A1 (fr) | 2017-12-22 | 2019-06-27 | Chemocentryx, Inc. | Composés cycliques fusionnés en 5,5 à substitution diaryle, utilisés en tant qu'inhibiteurs du c5ar |
JP7254082B2 (ja) | 2017-12-22 | 2023-04-07 | ケモセントリックス,インコーポレイティド | C5aR阻害剤としてのジアリール置換6,5-縮合環化合物 |
MX2020010390A (es) * | 2018-04-02 | 2021-01-15 | Chemocentryx Inc | Profarmacos de antagonistas de c5ar biciclicos fusionados. |
CN115515961A (zh) * | 2020-05-07 | 2022-12-23 | Ac免疫有限公司 | 用于诊断的新化合物 |
CN117460731A (zh) * | 2021-06-11 | 2024-01-26 | 劲方医药科技(上海)有限公司 | 杂环内酰胺类化合物,其制法与医药上的用途 |
KR20240046550A (ko) * | 2021-08-11 | 2024-04-09 | 란도스 바이오파마, 인크. | Nlrx1의 테트라히드로피라졸로피리딘-유사체 리간드 및 그의 용도 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3365459A (en) * | 1964-09-08 | 1968-01-23 | Ciba Geigy Corp | Certain tetrahydro pyrazolo-pyridine and pyrazolo-piperidine derivatives |
US3340269A (en) * | 1964-09-08 | 1967-09-05 | Ciba Geigy Corp | 1-substituted 4-acyl-2, 3-dioxo-piperidine |
GB8613591D0 (en) * | 1986-06-04 | 1986-07-09 | Roussel Lab Ltd | Chemical compounds |
DE3775527D1 (de) * | 1986-10-22 | 1992-02-06 | Ciba Geigy Ag | 1,5-diphenylpyrazol-3-carbonsaeurederivate zum schuetzen von kulturpflanzen. |
PH27357A (en) * | 1989-09-22 | 1993-06-21 | Fujisawa Pharmaceutical Co | Pyrazole derivatives and pharmaceutical compositions comprising the same |
FR2665898B1 (fr) * | 1990-08-20 | 1994-03-11 | Sanofi | Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
FR2714057B1 (fr) * | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
US5596106A (en) * | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
FR2741621B1 (fr) * | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
FR2742148B1 (fr) * | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
WO1998031227A1 (fr) * | 1997-01-21 | 1998-07-23 | Smithkline Beecham Corporation | Nouveaux modulateurs de recepteurs de cannabinoides |
FR2758723B1 (fr) * | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
FR2761266B1 (fr) * | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates |
KR100652994B1 (ko) * | 1998-09-11 | 2006-11-30 | 아방티 파르마 소시에테 아노님 | 아제티딘 유도체, 이의 제조방법 및 이를 함유하는 약제 |
FR2789079B3 (fr) * | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
CA2399791A1 (fr) * | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Modulateurs de recepteurs aux cannabinoides, leurs procedes de preparation et utilisations de modulateurs de recepteurs aux cannabinoides pour le traitement de maladies respiratoires et non respiratoires |
US6479479B2 (en) * | 2000-03-03 | 2002-11-12 | Aventis Pharma S.A. | Azetidine derivatives, their preparation and pharmaceutical compositions containing them |
US6355631B1 (en) * | 2000-03-03 | 2002-03-12 | Aventis Pharma S.A. | Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation |
US6566356B2 (en) * | 2000-03-03 | 2003-05-20 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation |
UA74367C2 (uk) * | 2000-03-23 | 2005-12-15 | Сольве Фармас'Ютікалз Б.В. | ПОХІДНІ 4,5-ДИГІДРО-1Н-ПІРАЗОЛУ, ЩО ВИЯВЛЯЮТЬ АНТАГОНІСТИЧНУ АКТИВНІСТЬ ЩОДО СВ<sub>1</sub>, СПОСІБ ЇХ ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЇЇ ВИГОТОВЛЕННЯ, СПОСІБ ЛІКУВАННЯ ЗАХВОРЮВАНЬ (ВАРІАНТИ) |
US20020019421A1 (en) * | 2000-07-05 | 2002-02-14 | Roni Biberman | Compositions and therapy for substance addiction |
US20020091114A1 (en) * | 2000-10-04 | 2002-07-11 | Odile Piot-Grosjean | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity |
AU2002319627A1 (en) * | 2001-07-20 | 2003-03-03 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
US6509367B1 (en) * | 2001-09-22 | 2003-01-21 | Virginia Commonwealth University | Pyrazole cannabinoid agonist and antagonists |
US20030139386A1 (en) * | 2001-12-21 | 2003-07-24 | Sophie Cote | Pharmaceutical compositions based on azetidine derivatives |
US6825209B2 (en) * | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
JP2006506366A (ja) * | 2002-10-18 | 2006-02-23 | ファイザー・プロダクツ・インク | カンナビノイド受容体リガンドおよびその使用方法 |
US7129239B2 (en) * | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) * | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US7329658B2 (en) * | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7176210B2 (en) * | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7145012B2 (en) * | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7268133B2 (en) * | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US7141669B2 (en) * | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
-
2004
- 2004-04-12 US US10/823,152 patent/US20040214856A1/en not_active Abandoned
- 2004-04-13 DE DE602004016839T patent/DE602004016839D1/de not_active Expired - Fee Related
- 2004-04-13 BR BRPI0409791-2A patent/BRPI0409791A/pt not_active IP Right Cessation
- 2004-04-13 EA EA200501504A patent/EA200501504A1/ru unknown
- 2004-04-13 ES ES04727076T patent/ES2309517T3/es not_active Expired - Lifetime
- 2004-04-13 CN CNA2004800175674A patent/CN1809566A/zh active Pending
- 2004-04-13 WO PCT/IB2004/001357 patent/WO2004094421A1/fr active IP Right Grant
- 2004-04-13 JP JP2006506562A patent/JP2006524225A/ja not_active Abandoned
- 2004-04-13 AU AU2004232552A patent/AU2004232552A1/en not_active Abandoned
- 2004-04-13 OA OA1200500291A patent/OA13047A/en unknown
- 2004-04-13 CA CA002521538A patent/CA2521538A1/fr not_active Abandoned
- 2004-04-13 AT AT04727076T patent/ATE409700T1/de not_active IP Right Cessation
- 2004-04-13 AP AP2005003427A patent/AP2005003427A0/xx unknown
- 2004-04-13 EP EP04727076A patent/EP1622903B1/fr not_active Expired - Lifetime
- 2004-04-13 MX MXPA05011454A patent/MXPA05011454A/es unknown
- 2004-04-13 KR KR1020057020010A patent/KR20060006048A/ko not_active Application Discontinuation
- 2004-04-16 CL CL200400827A patent/CL2004000827A1/es unknown
- 2004-04-20 PA PA20048600601A patent/PA8600601A1/es unknown
- 2004-04-20 GT GT200400076A patent/GT200400076A/es unknown
- 2004-04-20 PE PE2004000389A patent/PE20050419A1/es not_active Application Discontinuation
- 2004-04-21 AR ARP040101339A patent/AR044037A1/es unknown
- 2004-04-21 UY UY28276A patent/UY28276A1/es not_active Application Discontinuation
- 2004-04-22 TW TW093111297A patent/TW200510419A/zh unknown
- 2004-04-23 NL NL1026027A patent/NL1026027C2/nl not_active IP Right Cessation
-
2005
- 2005-09-29 IS IS8054A patent/IS8054A/is unknown
- 2005-10-21 TN TNP2005000272A patent/TNSN05272A1/fr unknown
- 2005-10-21 MA MA28565A patent/MA27766A1/fr unknown
- 2005-10-21 ZA ZA200508568A patent/ZA200508568B/en unknown
- 2005-10-21 CO CO05106974A patent/CO5640084A2/es not_active Application Discontinuation
- 2005-10-21 EC EC2005006117A patent/ECSP056117A/es unknown
- 2005-11-22 NO NO20055516A patent/NO20055516L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PE20050419A1 (es) | 2005-06-18 |
IS8054A (is) | 2005-09-29 |
CN1809566A (zh) | 2006-07-26 |
GT200400076A (es) | 2004-12-16 |
UY28276A1 (es) | 2004-11-30 |
CA2521538A1 (fr) | 2004-11-04 |
TNSN05272A1 (fr) | 2007-07-10 |
NL1026027A1 (nl) | 2004-10-27 |
NO20055516L (no) | 2005-11-22 |
CO5640084A2 (es) | 2006-05-31 |
OA13047A (en) | 2006-11-10 |
US20040214856A1 (en) | 2004-10-28 |
ES2309517T3 (es) | 2008-12-16 |
AP2005003427A0 (en) | 2005-12-31 |
PA8600601A1 (es) | 2005-05-24 |
CL2004000827A1 (es) | 2005-03-04 |
BRPI0409791A (pt) | 2006-05-30 |
NL1026027C2 (nl) | 2005-07-05 |
ECSP056117A (es) | 2006-03-01 |
WO2004094421A1 (fr) | 2004-11-04 |
AU2004232552A1 (en) | 2004-11-04 |
JP2006524225A (ja) | 2006-10-26 |
EP1622903B1 (fr) | 2008-10-01 |
EP1622903A1 (fr) | 2006-02-08 |
KR20060006048A (ko) | 2006-01-18 |
ATE409700T1 (de) | 2008-10-15 |
AR044037A1 (es) | 2005-08-24 |
ZA200508568B (en) | 2007-04-25 |
EA200501504A1 (ru) | 2006-04-28 |
TW200510419A (en) | 2005-03-16 |
MXPA05011454A (es) | 2005-12-12 |
DE602004016839D1 (de) | 2008-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27766A1 (fr) | Ligands de recepteurs de cannabinoides et leurs utilisations | |
MA27853A1 (fr) | LIGANDS DES RECEPTEURS DE CANNABINOiDES ET LEURS UTILISATIONS | |
MA27767A1 (fr) | Ligands des recepteurs de cannabinoides et leurs utilisations | |
MA27479A1 (fr) | PURINES ET LEURS UTILISATIONS COMME LIGANDS DES RECEPTEURS DE CANNABINOiDES | |
TNSN05190A1 (fr) | DERIVES DE PYRAZOLO [1,5-a][1,3,5] TRIAZINE SERVANT DE LIGANDS DES RECEPTEURS DE CANNABINOIDES | |
MA28935B1 (fr) | Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite | |
BRPI0409634A (pt) | ligantes de receptores de canabinóides e utilização destes | |
BRPI0411617A (pt) | derivados de pirimidina como ligantes de receptores de canabinóides | |
HRP20040684A2 (en) | 2,4-pyrimidinediamine compounds and their uses | |
FR16C0028I2 (fr) | Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques | |
ATE526991T1 (de) | Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen | |
EA200700934A1 (ru) | Производные пиримидина и их применение в качестве модуляторов cb2 | |
MA31183B1 (fr) | Inhibiteurs de mek | |
MXPA05011922A (es) | Ligandos del receptor de cannabinoides y sus usos. | |
ATE433973T1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
EA200501667A1 (ru) | Рецепторный комплекс тканезащитных цитокинов, способы идентификации тканезащитных соединений и их применение | |
DE60309739D1 (de) | Pyridinderivate als modulatoren des cb2-rezeptors | |
MA28680B1 (fr) | 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines | |
NO20073574L (no) | Triazolsubstituerte aminobenzofenonforbindelser | |
MA30485B1 (fr) | Aminothiazoles et leurs utilisations | |
ATE340785T1 (de) | 2-phenylamino-4-trifluoromethyl-5-(benzyl- oder pyridin-4-ylmethyl)carbamoylpyrimidin-derivate als selektive cb2 cannabinoid-rezeptor modulatoren | |
GT200400231A (es) | Compuestos de sulfoniltetrahidro-3h-benzo(e)indol-8-amina como ligandos de la 5-hidroxitriptamina-6. | |
NO20060420L (no) | 2-aminobenzoylderivater | |
FR2842422B1 (fr) | Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations | |
EA200600314A1 (ru) | Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях |